Mesoblast Investor Relations Material
Latest events
H1 2025
Mesoblast
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Mesoblast Limited
Access all reports
Mesoblast Limited is an Australian biotechnology company that develops cellular medicines based on mesenchymal lineage cells. The company’s pipeline targets inflammatory and cardiovascular diseases, with therapies in various stages of clinical development. Its operations include research, regulatory affairs, and strategic licensing. Mesoblast Limited is headquartered in Melbourne, Australia, and its shares are listed on the ASX.
Key slides for Mesoblast Limited
Q4 2024
Mesoblast Limited
International Society for Cell & Gene Therapy North America Virtual Town Hall
Mesoblast Limited
Latest articles
)
Airbnb: The Hospitality Giant Without Property
Airbnb has grown from an idea to help the Co-Founders make rent, to one of the most dominant companies in the global hospitality industry.
13 Jun 2025
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
Ticker symbol
MSB
Country
🇦🇺 Australia